ArticleFrontiers in public health2026
Prevalence and genotype distribution of human papillomavirus in cervical cancer and precancer in Japan between 2012 and 2025: a retrospective single-center study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to provide the latest data on the distribution of human papillomavirus (HPV) genotypes in cervical cancer and precancer at a single university hospital in Tokyo, Japan, between 2012 and 2025. Methods: Cervical exfoliated cell specimens collected from 2,536 women with histologically confirmed, cervical intraepithelial neoplasia 2 (CIN2), CIN3, squamous cell carcinoma (SCC), adenocarcinoma Results: Overall, HPV positivity was 96.6%, with high detection rates in CIN2 (98.5%), CIN3 (98.2%), and SCC (96.1%), and slightly lower rates in ADC (78.3%). In squamous lesions, HPV16 infections were the most prevalent and increased progressively with lesion severity (33.2% in CIN2, 50.1% in CIN3, 61.7% in SCC). Prevalence ratio analysis demonstrated a significantly higher prevalence of HPV16 in CIN3 versus CIN2 and in SCC versus CIN3, supporting its strong association with progression to invasive cancer. In contrast, HPV52 and HPV58 infections decreased with disease progression. In glandular lesions, HPV16 and HPV18 predominated across AIS, ASC, and ADC. Among ADC subtypes, usual-type ADC showed the highest HPV positivity (89.8%), whereas endometrioid, minimal deviation, serous, and clear-cell subtypes showed low or absent HPV positivity, highlighting the etiologic heterogeneity of ADC. Among single-type infection cases, the proportion of lesions attributable to vaccine-preventable types (HPV16/18) increased with severity in squamous lesions (31.9% in CIN2 to 72.2% in SCC) and remained consistently high in glandular lesions (>94%). Regarding HPV16/18/31/33/45/52/58, potential coverage exceeded 87% in CIN2 and 92% in SCC. Conclusion: These findings confirm the central role of HPV16 in cervical carcinogenesis, and highlight the contribution of HPV52 and HPV58 in precancerous lesions, which further underscores the need for the widespread adoption of the nonavalent vaccine in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.